PatentsUSA
Supreme Court to Define Limits of Induced Patent Infringement Liability in Generic Drug Advertising
The U.S. Supreme Court has granted certiorari in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. to clarify when advertising a generic drug as a ‘generic’ for a patented brand-name drug can lead to liability for induced patent infringement. The case focuses on ‘skinny label’ generics approved for non-patented us…
Thursday, February 12, 2026